Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Kyprolis

- PMLiVE

Imbruvica gains expanded use in Europe

Rival Calquence receives accelerated review in US

- PMLiVE

J&J files new Darzalex formulation in US and Europe

Subcutaneous version could help fend of Sanofi rival

- PMLiVE

FDA verdict on Sanofi’s Darzalex rival is due in April 2020

One of several anti-CD38 antibodies in pipeline

- PMLiVE

J&J takes option on Genmab follow-up to Darzalex

Blockbuster partners look to next chapter - while takeover talk persists

- PMLiVE

Encouraging early data for Amgen’s BiTE therapies

Including first-in-man data from prostate cancer drug

- PMLiVE

After discount row, NICE finally says yes to first line Revlimid

England catches up with rest of Europe

- PMLiVE

Poseida gets Novartis backing for myleoma CAR-T challenger

San Diego firm joins crowded field

- PMLiVE

Janssen looks to expand Darzalex in Europe

Regimen reduced risk of disease progression or death by 44%

- PMLiVE

GSK’s myeloma drug hits target, prompting rapid filing pledge

Antibody drug conjugate could challenge CAR-Ts

- PMLiVE

Roche, AbbVie hit by clinical hold for Venclexta in myeloma

Safety concerns could hit blockbuster expectations

- PMLiVE

NICE partially clears Darzalex combo in blood cancer

Approved in second-line use under  CDF

- PMLiVE

AbbVie enters BCMA race with Teneobio deal

Agreement includes option to acquire TeneoOne

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links